Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01015911 (Clinical Trial / Vorsetuzumab Mafodotin / SGN-75)

Study Title
A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma (NCT01015911)

Trial Description
This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of the antibody-drug conjugate SGN-75 (vorsetuzumab mafodotin) in patients with CD70-positive relapsed or refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.

This trial is sponsored by Seattle Genetics. [1]

Study Data

  • Condition:
    • Renal Cell Carcinoma
    • Non-Hodgkin Lymphoma
  • Interventions:
    • Drugs used in this trial
      • SGN-75 (vorsetuzumab mafodotin; Seattle Genetics)
  • Phase: I
  • Enrollment: 58
  • Start: November 2009
  • Completion: March 2012
  • Last verified: December 2014

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: July 14, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar